Knoa Pharma: Back Pain trials

The registry lists 10 Back Pain studies with Knoa Pharma as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 3 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01452529Phase 3Results posted
Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01358526Phase 3Results posted
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015TerminatedNCT01125917Phase 3Results posted
Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT00490919Phase 3Results posted
The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.CompletedNCT00315445Phase 3Results posted
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back PainTerminatedNCT00313014Phase 3Results posted
A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainCompletedNCT01427283Phase 3
Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back PainCompletedNCT01427270Phase 3
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.CompletedNCT00315887Phase 3
The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.CompletedNCT00315874Phase 3

All Back Pain studies →Knoa Pharma: all focus areas →